Humacyte, Inc. (HUMA) vs Outlook Therapeutics, Inc. (OTLK)
- Humacyte, Inc. HUMA 0.43 −2.27%
- Outlook Therapeutics, Inc. OTLK 0.49 −2.00%
Humacyte, Inc. and Outlook Therapeutics, Inc. are both Biotechnology companies. Humacyte, Inc. and Outlook Therapeutics, Inc. are of similar size ($122.1M and $121.7M). Humacyte, Inc. grew revenue faster over the last twelve months: 149.8% against −113.6%. Outlook Therapeutics, Inc. has the higher net margin (5,253.4% vs −4,448.9%) and the higher return on invested capital (0.00% vs −433.7%). Across the 15 metrics below, Outlook Therapeutics, Inc. leads on 10 and Humacyte, Inc. on 5.
Valuation
Profitability
| Metric | HUMA | OTLK | Biotechnology median |
|---|---|---|---|
| Gross margin | (494.58%) | 195.62% | 65.16% |
| Operating margin | (5,240.78%) | 4,781.76% | 0.00% |
| Net margin | (4,448.89%) | 5,253.40% | 0.00% |
| Free cash flow margin | (4,599.72%) | 4,826.38% | 0.00% |
| Return on equity | (534.42%) | 256.92% | (56.36%) |
| Return on assets | (68.16%) | (251.66%) | (48.04%) |
| Return on invested capital | (433.66%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack